Assessing TD’s Impact Using Clinician-Reported Measures: A Poster from Psych Congress Elevate

Host: Ashley Baker, MSN, PMHNP
Guest: Stacy Finkbeiner, PhD

The IMPACT-TD Registry is an ongoing, real-world observational study that aims to better understand the multidimensional impacts of tardive dyskinesia (TD) on patients’ lives. To achieve this goal, the IMPACT-TD Scale was developed and used by clinicians involved with the study, and now the results from the interim analysis are available. Joining psychiatric nurse practitioner Ashley Baker to share the key findings on TD’s impact from the clinician perspective is Dr. Stacy Finkbeiner, U.S. Medical Director at Teva Pharmaceuticals.